Citigroup
ANVS icon

Citigroup’s Annovis Bio ANVS Stock Holding History

Citigroup’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Sell
3
-52
-95% -$101 ﹤0.01% 5609
2026
Q1 		$123 Buy
55
+54
+5,400% +$148 ﹤0.01% 5599
2025
Q4 		$3 Buy
+1
New +$3 ﹤0.01% 5894
2024
Q1 		– Sell
-11,197
Closed -$209K – 5628
2023
Q4 		$209K Buy
+11,197
New +$99.3K ﹤0.01% 3893
2023
Q1 		– Sell
-6
Closed -$81 – 5471
2022
Q4 		$81 Hold
6
– – ﹤0.01% 5647
2022
Q3 		$0 Buy
6
+1
+20% +$13 ﹤0.01% 5796
2022
Q2 		$0 Sell
5
-70
-93% -$765 ﹤0.01% 6207
2022
Q1 		$1K Buy
75
+70
+1,400% +$1.01K ﹤0.01% 6139
2021
Q4 		$0 Buy
+5
New +$129 ﹤0.01% 5798
2021
Q2 		– Sell
-303
Closed -$8K – 6107
2021
Q1 		$8K Buy
+303
New +$6.48K ﹤0.01% 5743

Other funds holding ANVS

EAM
Empery Asset Management New York $86.5M AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citigroup's ANVS Position: Q2 2026 in Review

Citigroup reduced its Annovis Bio (ANVS) stake by 95% in Q2 2026, selling an estimated $101 and leaving 3 shares worth $6. The position accounts for ﹤0.01% of the portfolio, ranked #5609.

Citigroup first reported a position in ANVS in Q1 2021 and has held it in 10 quarters since. The position peaked at $209K in Q4 2023. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

  • Citigroup held 3 shares of Annovis Bio worth $6 as of Q2 2026.
  • Citigroup sold 52 Annovis Bio shares in Q2 2026, an estimated $101.
  • Annovis Bio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5609 holding.
  • Citigroup first reported a position in Annovis Bio in Q1 2021 and has held it in 10 quarters since.
  • Citigroup's Annovis Bio position peaked at $209K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.